LeonaBio, Inc. Rebrands, Changes Ticker to LONA Following Transformative Acquisition and Financing

summarizeSummary

LeonaBio, Inc. (formerly Athira Pharma, Inc.) announced a corporate rebranding, including a name and ticker symbol change to "LONA," to reflect its recent transformative acquisition of a Phase 3 breast cancer program and significant financing.

check_boxKey Events

• Corporate Rebranding

  Athira Pharma, Inc. officially changed its name to LeonaBio, Inc. and will trade under the new ticker symbol "LONA" on The Nasdaq Capital Market, effective January 12, 2026.

• Strategic Rationale

  The rebranding reflects a transformative acquisition of rights to a Phase 3 program for metastatic breast cancer (lasofoxifene) and a recent $90 million financing, providing capital through 2028.

• Executive Compensation Update

  The Chief Financial Officer, Robert Renninger, received an amended change in control and severance agreement and an increase in annual base salary to $460,000.

auto_awesomeAnalysis

The company's rebranding to LeonaBio, Inc. and new ticker symbol "LONA" signals a major strategic pivot following its recent acquisition of rights to a Phase 3 metastatic breast cancer program (lasofoxifene) and a substantial $90 million financing. For a micro-cap company, this move indicates a renewed focus, a de-risked financial runway into 2028, and a commitment to advancing late-stage assets. This strategic shift, highlighted by the corporate identity change, is a significant positive development for the company's future prospects. Additionally, the CFO's severance agreement was amended, and their annual base salary was increased to $460,000, which are routine compensation adjustments.